Development of an App to engage patients at risk of osteoarthritis

开发一款应用程序来吸引有骨关节炎风险的患者

• 批准号: ES/Y007751/1
• 负责人: Suzanne Eldridge
• 金额: $ 6.53万
• 依托单位: Queen Mary University of London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=ES%2FY007751%2F1
• 关键词: Development; App; engage; patients; risk

Osteoarthritis is a degenerative joint disease, characterised by cartilage loss, for which there is no cure. It causes joint pain, and it is a leading cause of disability worldwide costing ~ 1.5-2% of the GDP. The cost to society for loss of working days was £2.58billion in 2017 (Versus Arthritis data). Analgesics reduce joint pain unsatisfactorily and physiotherapy can, at best, marginally delay the need for joint replacement. Joint replacement restores some degree of independence but not full function to the standards of an active lifestyle of an increasingly younger patient population. In 20% of the cases does not live up to patients' expectations. A number of drugs have been developed in recent years (Sprifermin, Loricivivint, LNA043) but have failed in clinical trials for either not providing pain relief or not restoring the cartilage properly, or both. Traumatic cartilage injuries lead to osteoarthritis later in life 39% of the time, but we do not understand why some patients progress and other don't. As part of a larger study we will be following these trauma patients up by MRI scans and muscle function tests. This project would enable the development of an App to obtain additional information about these patients during their recovery, or lack of. This resource would be invaluable to the scientific community, clinicians and the pharmaceutic industry to provide better healthcare early on and enable healthy ageing.

骨关节炎是一种退行性关节疾病，以软骨丧失为特征，目前尚无治愈方法。它导致关节疼痛，是世界范围内导致残疾的主要原因，占GDP的1.5-2%。2017年，工作日损失给社会造成的成本为25.8亿英镑（对比关节炎数据）。止痛剂不能令人满意地减轻关节疼痛，物理治疗最多只能略微推迟关节置换术的需要。关节置换术在一定程度上恢复了患者的独立性，但对越来越年轻的患者来说，并不能完全达到积极生活方式的标准。在20%的病例中没有达到患者的期望。近年来已经开发了许多药物（Sprifermin, Loricivivint, LNA043），但在临床试验中失败，要么不能缓解疼痛，要么不能正常恢复软骨，或者两者兼而有之。外伤性软骨损伤在39%的情况下会导致骨性关节炎，但我们不明白为什么有些患者会进展，而有些则不会。作为一个更大的研究的一部分，我们将通过核磁共振扫描和肌肉功能测试跟踪这些创伤患者。该项目将开发一款应用程序，以获取这些患者在康复期间或缺乏康复期间的额外信息。这一资源对于科学界、临床医生和制药行业来说是非常宝贵的，可以在早期提供更好的医疗保健，并使健康老龄化成为可能。